**Supplementary Table S1** Serious infections up to week 96 (safety population)

|  |  |  |
| --- | --- | --- |
|  | **Double-blind period** | **Open-label period** |
|  | **Placebo****QW SC****n = 44** | **Tocilizumab****162 mg QW SC****n = 43** | **Placebo- tocilizumab****162 mg QW SC****n = 31** | **Continuous-tocilizumab****162 mg QW SC****n = 30** |
| Total number of events | 4 | 12 | 6 | 0 |
| Infected skin ulcer  | 0 | 2 (4.7) | 2 (6.5) | 0 |
| Osteomyelitis | 1 (2.3) | 2 (4.7) | 1 (3.2) | 0 |
| Pneumonia | 1 (2.3) | 1 (2.3) | 0 | 0 |
| Appendicitis | 0 | 0 | 1 (3.2) | 0 |
| Bronchitis | 0 | 1 (2.3) | 0 | 0 |
| Device-related infection | 0 | 1 (2.3) | 0 | 0 |
| Lung infection | 0 | 1 (2.3) | 0 | 0 |
| Oesophageal candidiasis | 0 | 1 (2.3) | 0 | 0 |
| Post-procedural cellulitis | 0 | 1 (2.3) | 0 | 0 |
| Sepsis | 0 | 1 (2.3) | 0 | 0 |
| Tuberculosis | 0 | 0 | 1 (3.2) | 0 |
| Cellulitis | 1 (2.3) | 0 | 0 | 0 |
| Lower respiratory tract infection | 1 (2.3) | 0 | 0 | 0 |

Data are shown as number of patients with event (%) unless stated otherwise.

QW, every week; SC, subcutaneously.